Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year
Viridian Therapeutics (VRDN) reported a 12.72% year-on-year increase in stock price, despite a 51.76% year-to-date decline. The company announced positive phase 3 trial results for its drug elegrobart in treating thyroid eye disease (TED), which could expand market opportunities if approved.
Topics: biotech clinical trial results drug development stock performance TED treatment